Table 3:

RANO Criteria for evaluation of glioma recurrence

RANO Guidelines	Response Criteria		Progression Criteria
	Complete	Partial
RANO-LGG PMID: 21474379	Requires all of the following: Complete disappearance of all T2/FLAIR disease for ≥4 weeks New or increased enhancement No new T2/FLAIR abnormalities other than what is attributable to treatment effects No more than physiological steroids, clinically stable or improved	Requires all of the following: ≥50 % decrease in the sum of perpendicular diameters of T2/FLAIR disease for≥4 weeks; No new or increased enhancement, No new T2/FLAIR abnormalities other than what is attributable to treatment effects, No more steroids than at the time of the baseline scan, clinically stable or improved	Defined by any of the following: Development of new lesions or increase of enhancement; ≥25 % increase in size of the T2/FLAIR abnormality on stable or increased doses of steroids and not attributable to radiation effect or comorbid events Definite clinical deterioration, death or loss to follow-up
RANO-HGG PMID: 20231676	Requires all of the following: Complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks No new lesions Stable or improved nonenhancing (T2/FLAIR) lesions Patients must be off corticosteroids (or on physiologic replacement doses only) And stable or improved clinically. Note: Patients with nonmeasurable disease only cannot have achieved CR; the best response possible is stable disease	Requires all of the following: ≥50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks No progression of nonmeasurable disease No new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan The corticosteroid dose at the time of scan evaluation should be no greater than the dose at time of baseline scan And stable or improved clinically	Defined by any of the following: ≥25% increase in the sum of the products of perpendicular diameters of enhancing lesions (compared with baseline if no decrease) on stable or increasing doses of corticosteroids; Significant increase in T2/FLAIR nonenhancing lesions on stable or increasing doses of corticosteroids compared with the baseline scan or the best response after initiation of therapy, not due to comorbid events; The appearance of any new lesions; Clear progression of nonmeasurable lesions; or definite clinical deterioration not attributable to other causes apart from the tumor or to a decrease in the corticosteroid dose